Spero Therapeutics (NASDAQ:SPRO) Price Target Lowered to $6.00 at HC Wainwright
Spero Therapeutics (NASDAQ:SPRO) Price Target Lowered to $6.00 at HC Wainwright
Spero Therapeutics (NASDAQ:SPRO – Get Rating) had its price target cut by HC Wainwright from $7.00 to $6.00 in a research note published on Monday morning, The Fly reports. They currently have a buy rating on the stock.
斯倍樂治療 (NASDAQ: SPRO — 獲得評分) 《蒼蠅》報告《蒼蠅》報導,HC 溫賴特將其價格目標從 7.00 美元降至 6.00 美元。他們目前對股票有買入評級。
Separately, Evercore ISI upgraded Spero Therapeutics from an in-line rating to an outperform rating and set a $8.00 price target for the company in a research note on Thursday, September 22nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $6.33.
另外,Evercore ISI 在 9 月 22 日(星期四)的一份研究報告中,將斯倍樂治療從在線評級升級為「跑贏大於」評級,並為該公司設定了 8.00 美元的目標價格。他們指出,這一舉動是一個估值電話。三位股票研究分析師對該股票進行了持有評級,其中兩位股票分析師為該公司分配了買入評級。根據來自 MarketBeat.com 的數據,該股票的共識評級為「保留」,平均目標價為 6.33 美元。
Spero Therapeutics Trading Up 6.1 %
斯倍樂治療交易增加 6.1%
Shares of SPRO stock opened at $2.09 on Monday. Spero Therapeutics has a 1-year low of $0.68 and a 1-year high of $19.87. The company has a market capitalization of $73.29 million, a price-to-earnings ratio of -0.60 and a beta of 1.87. The stock's fifty day simple moving average is $0.95 and its 200-day simple moving average is $2.61.
SPRO 股票於星期一開盤價為 2.09 美元。斯倍樂治療有 1 年低點 0.68 美元和 1 年高點 19.87 美元。該公司的市值為 73.29 萬美元,價格與收益比為 -0.60,測試版為 1.87。該股的五十天簡單移動平均線為 0.95 美元,其 200 天的簡單移動平均線為 2.61 美元。
Insider Buying and Selling at Spero Therapeutics
斯倍樂治療的內幕購買和銷售
Institutional Investors Weigh In On Spero Therapeutics
機構投資者權衡斯倍樂治療
A number of institutional investors have recently made changes to their positions in SPRO. Rock Springs Capital Management LP raised its position in Spero Therapeutics by 4.8% during the first quarter. Rock Springs Capital Management LP now owns 990,913 shares of the company's stock valued at $8,621,000 after purchasing an additional 45,600 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Spero Therapeutics during the first quarter valued at about $225,000. Eversept Partners LP acquired a new position in shares of Spero Therapeutics during the first quarter valued at about $519,000. AQR Capital Management LLC acquired a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $115,000. Finally, XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics in the 1st quarter worth about $115,000. Institutional investors own 57.38% of the company's stock.
一些機構投資者最近對其在 SPRO 的倉位進行了更改。岩泉資本管理有限責任公司在斯倍樂治療第一季度提高了 4.8% 的地位。石泉資本管理有限公司在上一季度額外購買 45,600 股股票後,擁有該公司股票價值 8,621,000 美元的 990,913 股股份。GSA 資本合作夥伴有限責任公司在第一季度收購了斯倍樂治療股份的新職位,價值約為 225,000 美元。永恒合作夥伴 LP 在第一季度收購了斯倍樂治療藥物股份的新職位,價值約為 $519,000。AQR 資本管理有限責任公司在第二季度收購了斯倍樂治療的新股份,價值約為 115,000 美元。最後,XTX 拓普有限公司在第一季度收購了斯倍樂治療的新股份,價值約為 115,000 美元。機構投資者擁有公司股票的 57.38%。
Spero Therapeutics Company Profile
斯倍樂治療公司簡介
(Get Rating)
(取得評分)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
斯倍樂治療, Inc. 是一家臨床階段生物製藥公司,致力於在美國識別、開發和商業化多重抗藥性 (MDR) 細菌感染和罕見疾病的治療方法。該公司的候選產品包括氫溴化替培南(HBR),一種用於治療複雜性尿路感染的口服碳青黴素類抗生素,包括成人腎盂腎炎;SPR206,一種直接代理 IV 給藥劑,用於治療醫院的 MDR 革蘭氏陰性細菌感染;以及用於治療非結核肺病的口服抗生素 SPR720。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Is the Market Overreacting with Shopify Stock?
- MO Money: Why Altria Group Stock is Rallying
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- 免費獲得斯倍樂治療研究報告
- 市場節拍播客, 3 個股票觀看紐蒙特礦業, 沃爾瑪, AMC
- 市場對 Shopify 股票的反應過度嗎?
- MO 貨幣:為什麼奧特利亞集團股票正在召集
- 美聯儲上調利率:3 隻股票觀察紐蒙特礦業,沃爾瑪,AMC
- 三個消費股可能在第四季度跑贏
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收斯倍樂治療日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收斯倍樂治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。